The Paige Prostate solution and Insight viewer are vendor-neutral and allow pathologists to view whole digitized slides from different sites and scanners.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
The firm said that receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally.
The two companies have been working together since February and now are formalizing plans to develop and test new products.
Philips said an AI prototype that evaluated combinations of vital signs and other biomarkers may predict infection up to 48 hours in advance of clinical suspicion.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The company said its APAS Independence platform can process 200 culture plates per hour and automatically remove nonsignificant plates from the workflow.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
A JAMA study found that low-value diagnostic tests are common in inpatient settings, and machine learning systems can be used to identify those tests and reduce their overutilization.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.